GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (BOM:532296) » Definitions » Forward PE Ratio

Glenmark Pharmaceuticals (BOM:532296) Forward PE Ratio : 0.00 (As of Jun. 01, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Forward PE Ratio?

Glenmark Pharmaceuticals's Forward PE Ratio for today is 0.00.

Glenmark Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Glenmark Pharmaceuticals's PE Ratio for today is 0.00.


Glenmark Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Glenmark Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Forward PE Ratio Chart

Glenmark Pharmaceuticals Annual Data
Trend 2018-12 2019-12 2020-09
Forward PE Ratio
20.62 10.42 14.25

Glenmark Pharmaceuticals Quarterly Data
2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06
Forward PE Ratio 16.67 18.76 21.01 20.62 19.12 12.45 12.24 10.42 5.96 13.97

Competitive Comparison of Glenmark Pharmaceuticals's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Forward PE Ratio falls into.



Glenmark Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Glenmark Pharmaceuticals  (BOM:532296) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Glenmark Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals (BOM:532296) Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (BOM:532296) Headlines

No Headlines